Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 13Breast Neoplasms, Male 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Intraductal, Noninfiltrating 2Recurrence 1Pancreatic Cyst 1Osteosarcoma 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Brain Neoplasms 1Advanced Cancer 1

Interventions

Temozolomide 107Radiotherapy 60Radiation 28Bevacizumab 19Magnetic Resonance Spectroscopy 16Nivolumab 15Surgical Procedures, Operative 12Irinotecan 11Cyclophosphamide 10Specimen Handling 9Chemotherapy, Adjuvant 9Radiotherapy, Intensity-Modulated 8Radiosurgery 8O(6)-benzylguanine 8Carmustine 8poly ICLC 7pembrolizumab 7motexafin gadolinium 7fludarabine 7Leukapheresis 7Flucytosine 7sargramostim 6Radiotherapy, Conformal 6Erlotinib Hydrochloride 6Lomustine 5Ipilimumab 5Imiquimod 5Imatinib Mesylate 5Hydroxyurea 5Granulocyte-Macrophage Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Glioblastoma × Tamoxifen × Clear all
NCT04200066 2022-08-22

A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

University of Rochester

Phase 1 Withdrawn
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡